Summary
Sobi presented new clinical and real-world evidence across four rare hematology franchises at EHA 2026: PNH (pegcetacoplan), ITP (avatrombopag), HLH (emapalumab), and myelofibrosis (pacritinib). While no pivotal efficacy readouts were disclosed, the package reinforces the commercial durability and clinical positioning of multiple approved products across orphan hematology markets.
What Happened
The company highlighted real-world evidence and post-hoc analyses supporting Aspaveli (pegcetacoplan), Doptelet (avatrombopag), Gamifant (emapalumab), and Vonjo (pacritinib). The presentations focus on treatment durability, clinical utilization, and longer-term outcomes rather than new registrational studies.
Deep Analysis
The most strategically important component is the PNH franchise. The PNH market has become one of the most competitive rare-disease hematology categories, with AstraZeneca’s Alexion franchise, Novartis’ iptacopan, and Sobi’s pegcetacoplan all competing for long-term patient retention. In this environment, real-world evidence becomes commercially important because efficacy differences between approved products can be difficult to demonstrate directly.
Pegcetacoplan remains differentiated through proximal complement inhibition at C3, allowing broader control of both intravascular and extravascular hemolysis. As newer competitors enter the market, durability and real-world outcomes increasingly determine prescribing behavior.
The HLH presentations are also noteworthy. Gamifant remains the only FDA-approved therapy for primary HLH, a devastating hyperinflammatory syndrome with limited therapeutic options. Continued evidence generation helps strengthen physician confidence in a very small but medically important market.
Pacritinib and avatrombopag represent mature assets, but ongoing analyses support lifecycle management and help defend market share against newer entrants.
Competitive Displacement
Pegcetacoplan competes directly with eculizumab, ravulizumab, and iptacopan in PNH. Avatrombopag faces competition from other thrombopoietin receptor agonists, while pacritinib continues to compete in specialized myelofibrosis populations. The EHA package is primarily defensive and franchise-supportive rather than disruptive.
Company / Product Background
Sobi has built one of the largest rare-disease hematology portfolios outside of major pharmaceutical companies. Its approved products span complement biology, platelet disorders, hyperinflammatory syndromes, and myeloproliferative neoplasms.
Signal Extraction
- Reinforces pegcetacoplan positioning in competitive PNH market
• Expands real-world evidence base across multiple rare hematology assets
• Supports long-term commercial durability of approved franchises
• Highlights continued leadership in HLH through Gamifant
• Portfolio-wide evidence generation strategy
Insilens Take
This is not a breakthrough-data event but a portfolio-strengthening event. The key signal is that Sobi continues to invest heavily in evidence generation around approved rare-disease assets. In orphan hematology markets, long-term commercial leadership is often determined by depth of evidence rather than headline efficacy alone.
